Presentations & Publications
Access a wide range of resources that provide detailed information on our products, programs, and collaborations.
Tolinapant (ASTX660) – Solid Tumors & Lymphomas
2019
- 2019 EORTC: Preliminary results of ASTX660, a novel non-peptidomimetic cIAP1/2 and XIAP antagonist, in 118 patients with solid tumors or lymphoma
- Xiao, et al. “Dual Antagonist of cIAP/XIAP ASTX660 Sensitizes HPV−and HPV+ Head and Neck Cancers to TNFα, TRAIL, and Radiation Therapy”
- 2019 EHA: ASTX660, a non-peptidomimetic antagonist of cIAP1/2 and XIAP, induces apoptosis in T cell lymphoma by enhancing immune mediated and death receptor dependent killing
- 2019 EHA: Preliminary Results of ASTX660, a Novel Non-Peptidomimetic cIAP1/2 and XIAP Antagonist, in Relapsed/Refractory Peripheral T-Cell Lymphoma and Cutaneous T-Cell Lymphoma
2014
2012
- 2012 Apoptosis and Cancer: A Potent XIAP And cIAP1 Dual Antagonist Is Effective In Melanoma Models
- 2012 EORTC: Characterization of a Potent XIAP & cIAP1 Dual Antagonist in Melanoma and Leukemia
- 2012 AACR: Discovery of potent dual inhibitors of both XIAP and cIAP using fragment based
- 2012 TAT: Discovery of Dual Antagonist of both XIAP and cIAP Using Fragment Based Drug Discovery
Presentations & Publications Archive
© Astex Pharmaceuticals
All rights reserved
